Compounded vs. Brand-Name Semaglutide: What's the Difference?

Brand-name semaglutide refers to medications manufactured under FDA-approved drug applications.

In the United States, FDA-approved semaglutide products include:

• Wegovy
• Ozempic
• Rybelsus

These aren't interchangeable simply because they contain semaglutide. They have different approved uses, doses, and formulations.

For example:

• Wegovy — FDA approved for chronic weight management in certain adults and adolescents, as well as certain cardiovascular-risk indications.
• Ozempic — FDA approved primarily for adults with type 2 diabetes, with additional cardiovascular and kidney-related indications.
• Rybelsus — an oral semaglutide product approved for adults with type 2 diabetes.

The important part is:

FDA has reviewed these specific finished products before approval.

That review includes evidence related to safety, effectiveness, manufacturing, quality, labeling, and dosing for their approved uses.

Compounded semaglutide is prepared by a pharmacy or other permitted compounder under applicable compounding laws.

The purpose of compounding is generally to create a medication for a patient whose medical needs may not be met by an available commercially manufactured product.

That could involve things such as:

• A different strength
• A different formulation
• Removing an ingredient
• or another clinically significant change determined by the prescriber.

But here's the key distinction:

Compounded semaglutide is not FDA approved.

The FDA does not review each compounded drug for safety, effectiveness, or quality before it reaches patients.

That doesn't mean compounding has no role in healthcare. It means compounded medication follows a different regulatory pathway from an FDA-approved commercial drug.

Imagine two approaches.

Brand-name semaglutide:

• A pharmaceutical company develops a specific formulation.
• It goes through the FDA approval process.
• It is manufactured according to the approved specifications.
• Patients receive that standardized commercial product.

Compounded semaglutide:

• A prescriber determines a compounded medication is appropriate for an identified patient.
• A qualified pharmacy prepares the prescribed formulation under applicable compounding rules.
• The finished compounded product itself does not go through FDA approval.

Same general medication conversation. Different product and different regulatory pathway.

No.

This is probably the most important misconception to clear up.

A true generic drug is FDA approved. It must meet FDA requirements demonstrating that it provides the same clinical benefit and risks as its brand-name counterpart.

Compounded semaglutide does not go through that generic-drug approval process. So phrases like:

• “Generic Ozempic”
• “Generic Wegovy”
• or “The same as Ozempic, just cheaper”

are misleading ways to describe a compounded product.

The FDA distinguishes compounded drugs from approved products: compounding does not confer FDA approval or establish therapeutic equivalence.

This is where the conversation becomes more nuanced.

Compounded medications can serve an important role when a patient's medical needs can't be met by an available FDA-approved product. The FDA itself recognizes that compounding can serve important patient needs.

For example, depending on the circumstances and applicable law, a prescriber may determine that an individual patient needs a clinically significant change to an available product.

Historically, compounding also played a major role while GLP-1 medications were listed on the FDA drug shortage list.

But the rules have changed as supplies stabilized.

The FDA explains that under section 503A, pharmacies generally cannot regularly compound products that are essentially copies of commercially available drugs unless applicable conditions are met, including situations where a prescriber documents a change that produces a significant difference for an individual patient.

That's important.

Compounded semaglutide isn't simply supposed to exist as “the cheaper copy of Wegovy.” Compounding has its own legal purpose and requirements.

The end of a shortage is not a blanket ban on every individualized compounded prescription, but it also does not authorize routine lower-cost copies. Requirements differ between section 503A pharmacies and section 503B outsourcing facilities. A prescriber must assess the individual medical need and the applicable legal pathway; affordability alone is not the patient-specific significant difference described in FDA’s policy.

See the FDA’s GLP-1 supply and compounding-policy update. This explains the regulatory distinction; it is not proof that a particular Luma prescription meets every requirement.

This question requires a little care.

Semaglutide itself is a GLP-1 receptor agonist.

But you shouldn't assume every compounded semaglutide product is identical to an FDA-approved commercial product in:

• Formulation
• Concentration
• Container
• Dosing instructions
• Inactive ingredients
• Quality controls

The FDA has specifically said compounded semaglutide products may differ from approved products in ways that can contribute to medication errors — for example, they may be dispensed in multi-dose vials or syringes with varying concentrations.

That's why the pharmacy and treatment instructions matter.

“Compounded semaglutide” is not one single standardized product.

Do Wegovy trial results apply to a compounded formulation?

A clinical trial evaluates the particular product, dose, population and protocol studied. Results for an FDA-approved semaglutide product do not establish the effectiveness, safety or therapeutic equivalence of a particular compounded formulation. Sharing a medication name is not evidence that the finished products produce identical outcomes.

When a program quotes a weight-loss percentage, ask which finished product was studied, for how long, and whether the data actually cover your prescription. The FDA’s unapproved GLP-1 guidance explains why approved-product review and compounded-product claims must be distinguished.

This confuses a lot of patients.

A brand-name pen may give you a predetermined dose.

A compounded medication may come in:

• A vial
• A prefilled syringe
• A different concentration

And instructions may involve measuring medication in milliliters or syringe units.

That's where mistakes can happen.

FDA has reported cases where patients accidentally administered multiple times their intended compounded semaglutide dose because of confusion around concentration and syringe measurements.

So if you're receiving compounded semaglutide, you should know exactly:

• Your prescribed dose
• The concentration of your medication
• How much to draw into the syringe
• How often to inject
• When your dose changes

You should never be guessing.

This is another distinction worth knowing.

The FDA has warned that some compounded products have used salt forms including:

• Semaglutide sodium
• and Semaglutide acetate

These are different active ingredients from the form used in FDA-approved semaglutide drugs.

The FDA says it does not have information showing that these salt forms have the same chemical and pharmacologic properties and has stated it is not aware of a lawful basis for their use in compounding under applicable federal conditions.

You don't need to memorize the chemistry. Just remember:

The exact form of semaglutide matters.

A reputable provider and pharmacy should know exactly what they're prescribing and dispensing.

Brand-name medications have an important advantage:

The finished product has undergone FDA review.

Its manufacturing specifications, approved dosing, labeling, safety data, and clinical evidence have been evaluated as part of the approval process.

Compounded drugs don't receive that same premarket review.

Because of that, the FDA states compounded drugs generally pose greater risk than FDA-approved products and recommends approved medications when available and appropriate.

That doesn't mean “every compounded medication is unsafe.” It means there is less FDA-level assurance about the finished compounded product.

That's why appropriate prescribing and pharmacy sourcing become even more important.

Compare the total amount you would actually pay, whether medication and care fees are included, and the required billing commitment. Insurance or manufacturer offers for an FDA-approved product have their own eligibility rules; they are not the same as a compounded program’s price.

Luma’s compounded semaglutide injection plans start at $99/mo on a new-user three-month plan ($297 upfront) or a current-user six-month plan ($594 upfront). Pay upfront or use Affirm, Klarna or Afterpay to split the payments, subject to eligibility and approval. See available plans for other billing options. Prices do not change by dose, and a lower price does not establish equivalent safety or results.

Brand-name GLP-1 medications are commercially manufactured pharmaceutical products, and their pricing can be substantial — especially when insurance doesn't cover the medication.

Compounded medications operate through a different supply and dispensing structure. That can sometimes result in lower patient pricing.

But price shouldn't be the only question. Instead of asking “What's the cheapest semaglutide I can find?”, ask:

• Who's prescribing it?
• Who is dispensing it?
• Is the medication clearly identified as compounded?
• Do I understand my dose?
• Is there healthcare support after it arrives?

Because saving money isn't helpful if you don't know what you're receiving or how to use it safely.

Some compounded formulations combine semaglutide with another ingredient, such as vitamin B12. You may see these promoted as offering additional benefits.

But there's an important regulatory point.

FDA explains that simply adding another ingredient such as B12 does not necessarily make a compounded semaglutide product legally distinct from a commercially available product.

Depending on the formulation, FDA may still consider it an essential copy unless the applicable requirements are met, including documentation that the change creates a significant difference for the identified patient.

So: “It has B12 added” doesn't automatically make compounding appropriate. The clinical reason for the compounded formulation matters.

Does adding B12 prove better weight loss or fewer side effects?

No such benefit is established by the sources cited in this article. Evidence for semaglutide alone, or for B12 alone, does not establish outcomes for the finished combination. Ask the prescriber what patient-specific need the added ingredient addresses, rather than treating more ingredients as proof of a better medication.

There's no single answer for everyone.

Brand-name semaglutide may make more sense when:

• An FDA-approved option is available and appropriate
• Insurance provides good coverage
• You prefer a standardized commercial product
• You want the FDA-reviewed formulation and delivery system

A compounded medication may be considered when:

• A licensed healthcare provider determines you have an individual medical need for a compounded formulation
• The compounded product is legally appropriate under the applicable circumstances
• A qualified pharmacy can prepare the prescribed formulation

The key is that the choice shouldn't simply come down to “brand = expensive, compounded = cheap.” It's a medical decision.

Whether you're receiving an FDA-approved product or a compounded medication, you shouldn't have to guess what you're getting.

A transparent provider should clearly explain:

Transparency should be part of the treatment — not something you have to investigate yourself.

At Luma, we believe patients should know exactly what type of medication they're being prescribed.

Treatment begins with a medical intake and review by a licensed healthcare provider.

When a medication is prescribed, the treatment plan should clearly identify whether the medication is an FDA-approved commercial product or a compounded medication.

When compounded treatment is medically and legally appropriate, it should be clearly disclosed as compounded and not FDA approved, with fulfillment through a qualified U.S.-based compounding pharmacy.

Patients should also receive clear instructions about their prescribed dose and how to administer it.

Because affordable care and transparent care shouldn't have to be opposites.

Brand-name semaglutide and compounded semaglutide are related — but they are not interchangeable categories.

Brand-name semaglutide is a standardized commercial medication that has gone through FDA review and approval for specific uses.

Compounded semaglutide is prepared under a separate compounding framework for appropriate patient needs and does not undergo FDA approval as a finished product.

Compounded semaglutide isn't “generic Ozempic.” And it shouldn't be presented as though it's identical to Wegovy or another FDA-approved medication.

But compounded medications can still serve an important role for certain patients when they're prescribed and prepared appropriately.

So rather than asking “Which one is the real semaglutide?”, a better question is: “Which treatment is medically appropriate for me — and do I understand exactly what I'm receiving?”

That's the kind of question good telehealth care should help you answer.